<DOC>
	<DOC>NCT01400776</DOC>
	<brief_summary>Study if WC3011 is effective and safe in the treatment of postmenopausal vaginal dryness due to vulvovaginal atrophy.</brief_summary>
	<brief_title>Safety &amp; Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<criteria>Postmenopausal females ≥35 years with either or both ovaries removed or naturally menopausal with moderate to severe vaginal dryness Hypersensitivity to estrogen and/or progestin therapy Known or suspected premalignant or malignant disease (except successfully treated skin cancers) Manifestation of or treatment for significant cardiovascular disease, Congestive heart failure, stroke or ischemic attacks Insulindependent diabetes mellitus Increased frequency or severity of headaches while on hormone or estrogen therapy Drug or alcohol addiction within last 2 years Participation in a clinical trial within 30 days Smoking ≥ 15 cigarettes daily Uncontrolled hypertension systolic blood pressure (BP) ≥ 160 mmHg or diastolic ≥ 95 mmHg</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Postmenopausal Women, Vaginal Dryness</keyword>
</DOC>